Pharvaris Bundle
What's the Story Behind Pharvaris?
Embark on a journey through the Pharvaris SWOT Analysis to uncover the fascinating narrative of a biopharmaceutical innovator. From its inception, Pharvaris has been at the forefront of developing groundbreaking treatments for rare diseases, particularly hereditary angioedema (HAE). Discover how this clinical-stage company is reshaping the landscape of HAE treatment with its novel approach.
Founded in 2015, Pharvaris has rapidly evolved, driven by a mission to provide more convenient and effective solutions for patients suffering from bradykinin-mediated conditions. The company's focus on oral bradykinin B2 receptor antagonists marks a significant shift from traditional injected therapies, offering hope for improved quality of life. With a strong financial standing, including €236 million in cash as of March 31, 2025, Pharvaris is poised to potentially revolutionize HAE and acquired angioedema (AAE) treatment, moving beyond the limitations of C1 inhibitor therapies.
What is the Pharvaris Founding Story?
The story of Pharvaris, a company focused on treating hereditary angioedema (HAE) and other bradykinin-mediated diseases, began in 2015. Founded by Berndt Modig, who currently serves as the Chief Executive Officer, the company's roots are in Leiden, Netherlands. This brief Pharvaris company history highlights its journey from inception to its current standing in the pharmaceutical landscape.
The founders identified a significant unmet need: the lack of convenient and effective oral therapies for HAE. At the time, patients primarily relied on injected treatments. This observation became the cornerstone of Pharvaris's mission, driving its focus on developing oral alternatives. The company's early business model centered on the discovery and development of novel oral bradykinin B2 receptor antagonists, a key area of research in HAE treatment.
Pharvaris's lead product candidate, PHA121 (also known as deucrictibant), is an orally available bradykinin B2-receptor antagonist. The company's financial journey includes a Series C financing round in November 2020, which raised an oversubscribed $80 million, bringing its total venture funding to over $160 million at that time. This round was co-led by Viking Global Investors and General Atlantic, with participation from Foresite Capital, Bain Capital Life Sciences, venBio Partners, and Venrock Healthcare Capital Partners. In June 2023, Pharvaris secured an additional $70 million in a private placement round, further supported by General Atlantic and venBio Partners, along with Bain Capital Life Sciences, Foresite Capital, and Venrock Healthcare Capital Partners. The founding team's expertise in pharmaceutical development and rare disorders, including HAE, led them to pursue this venture, aiming to offer oral alternatives to patients.
Pharvaris: Founding and Early Development
Pharvaris was established in 2015 by Berndt Modig in Leiden, Netherlands. The company's initial focus was on addressing the unmet need for oral therapies for hereditary angioedema (HAE).
- The company's lead product candidate is PHA121 (deucrictibant), an oral bradykinin B2-receptor antagonist.
- Early funding included an $80 million Series C round in November 2020, bringing total venture funding to over $160 million.
- In June 2023, Pharvaris raised an additional $70 million in a private placement round.
- The company's mission is to develop oral alternatives for HAE patients, aiming to improve treatment convenience.
For more insights into the competitive environment, consider exploring the Competitors Landscape of Pharvaris.
Pharvaris SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Pharvaris?
The early growth of Pharvaris, a company focused on treating hereditary angioedema (HAE), has been marked by significant advancements in its clinical development pipeline. Founded in 2015, the company initially concentrated on the preclinical and early clinical stages of deucrictibant, its oral bradykinin B2 receptor antagonist. This strategic focus has positioned Pharvaris for potential commercialization. The company's journey reflects its commitment to addressing unmet medical needs in the HAE treatment landscape.
Clinical Development Milestones
A key milestone in Pharvaris's early development was the initiation of the RAPIDe-1 Phase 2 study. This study focused on the on-demand treatment of HAE attacks using deucrictibant. Positive results from this study were instrumental in advancing the drug's development.
Team Expansion and Regulatory Recognition
To support launch preparedness and overall business growth, Pharvaris strategically expanded its team. This included key hires in sales, marketing, and business development. Pharvaris also gained regulatory recognition, including orphan drug designation from the U.S. Food and Drug Administration (FDA) in March 2022, and from the European Commission (EC) on March 28, 2025, for the treatment of bradykinin-mediated angioedema.
Financial Performance and Investment
Pharvaris maintained a strong financial position, with cash and cash equivalents of €281 million as of December 31, 2024, and €236 million as of March 31, 2025. Research and development (R&D) expenses increased to €30.9 million for Q1 2025, up from €18.5 million in Q1 2024, and a net loss of €46.3 million for Q1 2025. These investments are directly correlated with the advancement of its late-stage clinical trials.
Strategic Focus and Future Outlook
The company's strategic focus has been on generating robust clinical data to build a compelling package for deucrictibant's efficacy and safety profile. This approach ensures its trajectory toward potential commercialization, aiming to provide effective HAE treatment options. To learn more about their core values, consider reading Mission, Vision & Core Values of Pharvaris.
Pharvaris PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Pharvaris history?
The Pharvaris company has achieved significant milestones in its development, particularly in the treatment of hereditary angioedema (HAE). These achievements highlight the company's progress in the biopharmaceutical industry.
| Year | Milestone |
|---|---|
| 2024 | Initiation of CHAPTER-3, a pivotal Phase 3 study for HAE prophylaxis. |
| 2025 | RAPIDe-3, a pivotal Phase 3 study for on-demand HAE treatment, reached target enrollment in March. |
| Ongoing | FDA granted TQT (thorough QT) study waivers for both deucrictibant formulations. |
| Ongoing | Deucrictibant received orphan drug designation in both the U.S. and Europe for bradykinin-mediated angioedema. |
A key innovation for Pharvaris is the development of two oral formulations of deucrictibant: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment of HAE attacks. This dual-pronged approach aims to provide comprehensive treatment options for patients, representing a significant advancement in HAE treatment.
Dual Formulations
The company developed both extended-release tablets and immediate-release capsules.
This allows for both preventative and on-demand treatment options.
Oral Administration
Both formulations are designed for oral administration.
This offers a more convenient option for patients compared to injectable treatments.
Targeted Treatment
The treatments are specifically designed to address HAE attacks.
This targets the underlying cause of the condition.
Regulatory Approvals
The FDA granted TQT (thorough QT) study waivers for both formulations.
This streamlines the development pathway.
Orphan Drug Designation
Deucrictibant received orphan drug designation in both the U.S. and Europe.
This designation supports the development of treatments for rare diseases.
Clinical Trials
The company is actively involved in Phase 3 clinical trials.
These trials are crucial for evaluating the efficacy and safety of the treatments.
Despite these advancements, Pharvaris has faced challenges, including substantial R&D expenses. The company reported a net loss of €46.3 million for Q1 2025, compared to €28.0 million for Q1 2024, driven by increased R&D expenditures, which rose by 67% year-over-year to €30.9 million. The company's cash position decreased by €45 million from Q4 2024 to Q1 2025.
Financial Losses
The company reported a net loss of €46.3 million for Q1 2025.
This is an increase from the €28.0 million loss in Q1 2024.
R&D Expenses
R&D expenditures increased by 67% year-over-year.
These expenses totaled €30.9 million in Q1 2025.
Cash Position
The company's cash position decreased by €45 million from Q4 2024 to Q1 2025.
This reflects an accelerated cash burn rate due to late-stage clinical trials.
Cash Runway
Pharvaris maintains a strong financial position.
It has an estimated cash runway into the third quarter of 2026.
Pipeline Expansion
The company is expanding its pipeline into acquired angioedema (AAE).
A clinical study is anticipated to begin in 2025.
Strategic Focus
The company is focused on developing treatments for bradykinin-mediated angioedema.
This includes both HAE and AAE.
Pharvaris Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Pharvaris?
The Pharvaris company journey since its inception in 2015 showcases its commitment to advancing treatments for bradykinin-mediated diseases. The company's story is marked by significant milestones in developing deucrictibant, its lead candidate, and strategic financial moves that have positioned it for future growth in the HAE treatment market.
| Year | Key Event |
|---|---|
| 2015 | Founded in Leiden, Netherlands, by Berndt Modig. |
| January 2016 | Secured its first funding round. |
| September 2019 | Closed a Series B financing round. |
| November 2020 | Completed an oversubscribed $80 million Series C financing, bringing total venture funding to over $160 million. |
| February 2021 | Converted to a public limited liability company, Pharvaris N.V., and went public on NASDAQ. |
| March 2022 | Deucrictibant received orphan drug designation from the U.S. FDA. |
| June 2023 | Raised $70 million in a private placement financing round. |
| 2024 | Initiated CHAPTER-3, a pivotal Phase 3 study for prophylactic treatment of HAE attacks. |
| March 2025 | RAPIDe-3, a pivotal Phase 3 study for on-demand HAE treatment, reached target enrollment of approximately 120 participants. |
| March 28, 2025 | The European Commission granted orphan designation to deucrictibant for bradykinin-mediated angioedema. |
| May 13, 2025 | Reported Q1 2025 financial results with cash and cash equivalents of €236 million. |
Future Clinical Data
Pharvaris anticipates announcing topline data from the RAPIDe-3 study in the first quarter of 2026. Data from the CHAPTER-3 study is expected in the second half of 2026. These results are crucial for the company's progress in HAE treatment.
Pipeline Expansion
A significant pipeline expansion is planned for 2025, with the initiation of a clinical study for deucrictibant in acquired angioedema due to C1-INH deficiency (AAE-C1INH). This demonstrates Pharvaris's commitment to addressing unmet medical needs.
Commercialization Readiness
The company is actively preparing for the potential commercialization of deucrictibant, pending regulatory submissions and approvals. Pharvaris is also expanding its team to support launch readiness. This is a key step towards bringing new therapies to patients.
Financial Position and Outlook
Pharvaris has a strong financial position, with an estimated cash runway extending into the third quarter of 2026. This financial stability supports the company's strategic investments and long-term goals. Pharvaris is focused on becoming a leader in bradykinin-mediated diseases.
Pharvaris Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of Pharvaris Company?
- What is Growth Strategy and Future Prospects of Pharvaris Company?
- How Does Pharvaris Company Work?
- What is Sales and Marketing Strategy of Pharvaris Company?
- What is Brief History of Pharvaris Company?
- Who Owns Pharvaris Company?
- What is Customer Demographics and Target Market of Pharvaris Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.